Beta-3 agonists clinical trials
A class of medicines: the studies that test any of its 3 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Adrenergic beta-3 Receptor Agonists.
Get an email when these change. Save the beta-3 agonists studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
150 studies that test it; most in 2016 (12)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 11 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 11 |
| 2016 | 12 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 9 |
| 2022 | 11 |
| 2023 | 8 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 69 · Other 85
Astellas Pharma Inc (33) · Astellas Pharma Europe B.V. (13) · Astellas Pharma Global Development, Inc. (5) · GlaxoSmithKline (5) · Far Eastern Memorial Hospital (4) · Mansoura University (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Cedars-Sinai Medical Center (3)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 154
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesityNot yet recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05713799Written as Mirabegron
- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseaseNot yet recruitingPhase 4VA Office of Research and DevelopmentNCT07187466Written as mirabegron
- Efficacy and Safety of Mirabegron in Intracerebral HemorrhageRecruitingPhase 2Tianjin Medical University General HospitalNCT05369351Written as Standard treatment+mirabegron
- Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionRecruitingPhase 4Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationNCT07310797Written as Mirabegron
- Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPHRecruitingPhase 4University of California, San FranciscoNCT07829029Written as Mirabegron
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in PrediabeticsRecruitingPhase 4Philip KernNCT05051436Written as Mirabegron 50 MG
- Mechanisms for Activation of Beige Adipose Tissue in HumansRecruitingPhase 2Philip KernNCT04666636Written as Mirabegron
- Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)RecruitingPhase 3University of AarhusNCT06551246Written as Mirabegron
- Beta-3 Enhanced Autonomic Therapy for POTSNot yet recruitingPhase 2Cedars-Sinai Medical CenterNCT07585513Written as Mirabegron
- Using Mirabegron to Control Arrhythmia-1Not yet recruitingPhase 2Cedars-Sinai Medical CenterNCT07566208Written as Mirabegron
- TReating Incontinence for Underlying Mental and Physical HealthRecruitingPhase 4University of California, San FranciscoNCT05362292Written as Mirabegron
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNERecruitingPhase 3Mansoura UniversityNCT07199894Written as Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
- Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related SymptomsRecruitingPhase 3Bir HospitalNCT06803030Written as Mirabegron 25 mg
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled TrialNot yet recruitingPhase 3Far Eastern Memorial HospitalNCT07114640Written as Mirabegron 25mg
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive BladderRecruitingPhase 4Mackay Memorial HospitalNCT06479720Written as Mirabegron with vaginal estrogen cream
- Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder SyndromeRecruitingPhase 4Walter Reed National Military Medical CenterNCT05221021Written as Mirabegron 50 MG [Myrbetriq]
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingPhase 2Zhejiang Provincial People's HospitalNCT06534762Written as Mirabegron
- A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)Not yet recruitingPhase 2Seoul National University HospitalNCT06181591Written as Mirabegron 50 MG
- Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus SolifenacinRecruitingPhase 3Far Eastern Memorial HospitalNCT04023253Written as Mirabegron
- Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled StudyRecruitingPhase 4Far Eastern Memorial HospitalNCT05946902Written as mirabegron
Codes
What other systems call Beta-3 agonists · ClinicalTrials.gg INT008928
- MeSH (NLM) D058667Adrenergic beta-3 Receptor AgonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D058667 | Adrenergic beta-3 Receptor Agonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.